Trial Profile
A phase II Study of Polatuzumab Vedotin (RO5541077) in Combination with Rituximab plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jun 2022
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Polatuzumab vedotin (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms P-DRIVE
- Sponsors Chugai Pharmaceutical
- 09 Jun 2022 Status changed from active, no longer recruiting to completed.
- 01 Jul 2021 Results published in the Cancer Science
- 23 Mar 2021 According to a Chugai Pharmaceutical media release, the Ministry of Health, Labour and Welfare (MHLW) approved Polivy (intravenous infusion 30mg and 140mg) in combination with bendamustine (freeze-dried formulation) and rituximab (BR therapy) for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).